top of page
This site was designed with the
.com
website builder. Create your website today.Start Now
Journal Publications

PUBLICATIONS

  1. Inhalable Particles Containing Isoniazid and Rifabutin as Adjunct Therapy for Safe, Efficacious and Relapse-Free Cure of Experimental Animal Tuberculosis in One Month: Amit singh, Rahul Kumar Verma,Amit Misra, (2021) Tuberculosis, 128: 102081. DOI: https://doi.org/10.1016/j.tube.2021.102081

  2. Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-A for site-specific and controlled drug delivery for cancer therapy: Kalpesh Vaghasiya, Eupa ray,Raghuraj singh,Krishna Jadhav,Ankur Sharma,Rehan Khan,Rahul Kumar Verma, (2021) Materials Science and Engineering: C, 123: 112027. DOI: https://doi.org/10.1016/j.msec.2021.112027

  3. Enema Based Therapy Using Liposomal Formulation of Low Molecular Weight Heparin for Treatment of Active Ulcerative Colitis: New Adjunct Therapeutic Opportunity  : Anas Ahmad# , Kalpesh Vaghasiya#, Ajay Kumar , Pravej Alam, Syed Shadab Raza, Rahul Kumar Verma*, Rehan Khan*, (2020) Materials Science and Engineering: C, NA: NA.

  4. Enteric-Coated Gelatin Nanoparticles Mediated Oral Delivery of 5-Aminosalicylic Acid Alleviates Severity of DSS-Induced Ulcerative Colitis: Anas Ahmad, Md. Meraj Ansari, Rakesh Kumar Mishra, Ajay Kumar, Akshay Vyawahare, Rahul Kumar Verma, Syed Shadab Raza, Rehan Khan*, (2020) Materials Science and Engineering: C, 119: 111582. DOI: 10.1016/j.msec.2020.111582

  5. Autophagy inducing inhalable Co-crystal formulation of Niclosamide-Nicotinamide for lung cancer therapy: Ray E, Vaghasiya K, Sharma A, Shukla R, Khan R, Kumar A, Verma RK*, (2020) AAPS PharmSciTech, 21: 1-14. DOI: 10.1208/s12249-020-01803-z

  6. Autophagy inducing inhalable Co-crystal formulation of Niclosamide-Nicotinamide for lung cancer therapy: Ray E, Vaghasiya K, Sharma A, Shukla R, Khan R, Verma RK*, (2020) AAPS PharmSciTech,, 21: 260. DOI: https://link.springer.com/article/10.1208/s12249-020-01803-z

  7. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defense peptide (HDP) in experimental tuberculosis: Sharma A,Vaghasiya K,Gupta P,Singh AK,Gupta UD,Verma RK*, (2020) Journal of Controlled Release, 324: 17-33 (IF:8:00). DOI: https://doi.org/10.1016/j.jconrel.2020.05.013

  8. Targeted pulmonary delivery of Epigallocatechin gallate (EGCG), a green tea polyphenol controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and supressing bacterial bu: Sharma A,Vaghasiya K,Ray E,Gupta P,Gupta UD,Singh AK,Verma RK*, (2020) ACS Biomaterials Science & Engineering, 6: 4126–4140 (IF:4.51). DOI: https://doi.org/10.1021/acsbiomaterials.0c00823

  9. Matrix metalloproteinase responsive mesoporous silica nanoparticles cloaked with cleavable-protein for “Self-actuating” on-demand controlled drug delivery for cancer therapy: Vaghasiya K, Ray E, Sharma A, Katare OP, Verma RK*, (2020) ACS Applied Bio Materials, 3: 4987–4999. DOI: https://doi.org/10.1021/acsabm.0c00497

  10. In vitro anti-tumoral and anti-bacterial activity of octamolybdate cluster-based hybrid solid incorporated with copper picolinate complex: Arti Joshi,Ruby Gupta, Kalpesh Vaghasiya,Rahul Kumar Verma,Deepika Sharma,Monika Singh*, (2020) ACS Applied Bio Materials, 3: 4025–4035. DOI: https://doi.org/10.1021/acsabm.0c00093

  11. Silymarin encapsulated nanoliquid crystals for improved activity against beta amyloid induced cytotoxicity: Singh A, Kumar A, Verma RK, Shukla R, (2020) International Journal of Biological Macromolecules, 7;149: 1198-1206 (IF:4.8). DOI: doi: 10.1016/j.ijbiomac.2020.02.041.

  12. Inhalation delivery of host defence peptides (HDP) using nano-formulation strategies: A pragmatic approach for therapy of pulmonary ailments.: Adlakha S, Sharma A, Vaghasiya K, Ray E,Verma RK*, (2020) Current Protein & Peptide Science, 21: 369 - 378 (IF:2.37). DOI: 10.2174/1389203721666191231110453

  13. Heparin encapsulated metered-dose topical “Nano-spray gel” liposomal formulation ensures rapid on-site management of frostbite injury by inflammatory cytokines scavenging: Vaghasiya K, Sharma A, Kumar K, Ray E, Adhlakha S, Katare OP, Hota S,Verma RK*, (2019) ACS Biomaterials Science & Engineering, 5: 6617-6631 (IF:4.51). DOI: https://doi.org/10.1021/acsbiomaterials.9b01486

  14. Polycaprolactone based nano-carrier for co-administration of moxifloxacin and rutin and its in-vitro evaluation for sepsis: Handa M, Sharma A,Verma RK,Shukla R, (2019) Journal of Drug Delivery Science and Technology, 56: 101286 (IF:2.60). DOI: 10.1016/j.jddst.2019.101286

  15. Alginate Micro-Spheres elicit innate Th1-inflammatory response in macrophages leading to bacillary killing: Vaghasiya K, Eram A, Sharma A, Ray E, Adlakha S,Verma RK*, (2019) AAPS PharmSciTech, 20(6): 241 (IF:2.82). DOI: 10.1208/s12249-019-1458-0

  16. Temperature/pH triggered PNIPAM based Smart nanogel system loaded with Anastrozole delivery for application in cancer chemotherapy AAPS PharmScitech: Handa M, Sharma A,Verma RK,Shukla R, (2019) AAPS PharmSciTech, 20(5): 213 (IF:2.82). DOI: 10.1208/s12249-019-1410-3

  17. Nanostructured silver decorated hollow silica and their application in treatment of microbial contaminated water at room temperature: Baruah A, Vaghasiya K, Ganguli AK,Verma RK ,Jha M, (2019) New Journal of Chemistry, 458(1): 84-89 (IF:3.06). DOI: 10.1039/C9NJ01049A

  18. Mycobactericidal activity of some micro-encapsulated synthetic Host Defense peptides (HDP) by expediting the permeation of antibiotic: A new paradigm of drug delivery for tuberculosis: Sharma A, Vaghasiya K, Gupta P, Gupta UD, Verma RK*, (2019) International Journal of Pharmaceutics, 10;558: 231-241 (IF:4.21). DOI: 10.1016/j.ijpharm.2018.12.076

  19. Nano-encapsulated HHC10 host defense peptide (HDP) reduces the growth of Escherichia coli via multimodal mechanisms.: Sharma A, Vaghasiya K, Ray E,Verma RK, (2018) Artificial Cells, Nanomedicine, and Biotechnology, 23: 1-10 (IF:4.46). DOI: 10.1080/21691401.2018.1489823

  20. Hollow ZnO from assembly of nanoparticles: photocatalytic and antibacterial activity: Zaidi Z, Vaghasiya K,Vijay A,Sharma M,Verma RK ,Vaidya S, (2018) Journal of Material Science, 53: 14964–14974 (IF:3.44). DOI: 10.1007/s10853-018-2715-4

  21. Timing feedback-inhibition of the reproductive hormone axis for male contraception: Malik R, Tondwal S, Venkatesh K.S, Gupta G, Shanker K,Verma RK,Misra A, (2018) Molecular Medicine (Indian Society for the Study of Reproduction and Fertility), 117-130.

  22. Lysosomal targeting strategies for design and delivery of bioactive for therapeutic interventions Journal of Drug Targeting: S harma A, Vaghasiya K, Ray E,Verma RK, (2018) Journal of Drug Targeting, 26: 208–221 (IF:3.40). DOI: 10.1080/1061186X.2017.1374390

  23. Reclaiming hijacked phagosomes: Hybrid nano-in-micro encapsulated MIAP peptide ensures host directed therapy by specifically augmenting phagosome-maturation and apoptosis in TB infected macro: Sharma A, Vaghasiya K, Gupta P,Singh A,Gupta UD,Verma RK*, (2018) International Journal of Pharmaceutics, 536 (1): 50-62 (IF:4.21). DOI: 10.1016/j.ijpharm.2017.11.046

  24. Hollow ZnO from assembly of nanoparticles: photocatalytic and antibacterial activity,: Z Zaidi, K Vaghasiya, A Vijay, M Sharma, RK Verma,Sonalika Vaidya, (2018) Journal of Materials Science, 53 (21): 14964-14974. DOI: 10.1007/s10853-018-2715-4

  25. Hybrid Nano-in-Micro systems for lung delivery of Host Defence Peptides (HDP) as adjunct therapeutics for Pulmonary TB: Sharma A,Verma RK, (2017) Journal of aerosol medicine and pulmonary drug delivery, 31 (2): A17-A17 (IF:2.86).

  26. Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and efficacy of amphotericin B: Pandya SK, Khare P, Tiwari B, Srinivasrao D, Dube A, Goyal N, Misra A, (2016) International Journal for Parasitology, 6(2): 125-132 (IF-3:00). DOI: 10.1016/j.ijpddr.2016.01.001

  27. Misdiagnosis Murder: disguised TB or Lung cancer: Vaghasiya K, Sharma A, (2016) Pulmonary Research and Respiratory Medicine, 3 (02): e5-e6. DOI: 10.17140/PRRMOJ-3-e006

  28. Inhalable microspheres with hierarchical pore size for tuning the release of biotherapeutics in lungs Microporous and Mesoporous Materials: Sharma A, Vaghasiya K,Verma RK, (2016) Microporous and Mesoporous Materials, 235: 195-203 (IF:4.2). DOI: 10.1016/j.micromeso.2016.08.009

  29. Lung Delivery of Anti-microbial Peptides (AMP) Using Dry Powder Inhalable Microspheres for Treatment of Pulmonary Tuberculosis: Respiratory drug delivery proceedings, (2015) 2: 339-344.

  30. Regulation of cell death by intracellular delivery of nitric oxide to macrophages infected with virulent or avirulent Mycobacterium tuberculosis: Verma RK, Misra A, (2015) Tuberculosis (Elsevier), 95 (5): 625-628 (IF:3:00). DOI: 10.1016/j.tube.2015.05.002

  31. Inhalation drug delivery devices: technology update: Ibrahim M, Garcia-Contreras L.,Verma RK, (2015) Medical Devices: Evidence and Research., 131-139 (IF:3:00). DOI: 10.2147/MDER.S48888

  32. Surface coating of doxorubicin loaded nanocapsule with alginate enhances its therapeutic efficacy through Th1 type immune response in Leishmania donovani infected hamsters: Kansal S,Tandon R, Verma A, Misra P, Choudhary AK, Verma PRP, Dube A, Mishra PR, (2014) British journal of Pharmacology (BJP), 171(17): 4038–4050 (IF:6.81). DOI: 10.1111%2Fbph.12754

  33. In Vitro Comparison of Two Nasal Delivery Devices to Administer Dry Powders: Garcia-Contreras L, (2014) Respiratory Drug Delivery (RDD), 156-161.

  34. Inhaled microparticles containing clofazimine are efficacious in the treatment of experimental tuberculosis in mice: Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, Gupta P, Gupta UD, Cholo M, Anderson R, Misra A,Fourie PB, (2013) Antimicrobial Agents and Chemotherapy (AAC), 57(2): 1050-1052. DOI: 10.1128/AAC.01897-12

  35. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill M. tuberculosis: Agrawal AK, Singh AK, Mohan M, Gupta A, Gupta P, Gupta UD, Verma PRP, Misra A, (2013) Tuberculosis ( Elsevier), 93(4): 412-417 (IF:3.00). DOI: 10.1016/j.tube.2013.02.012

  36. Bacterial DNA gyrase is not the target of quinoline based anti-tubercular compounds International Research: Tripathy RK, Paul MK, Nayyar A, Jain R,Mukhopadhayay AK, (2013) journal of Pharmacy(IJRP), 4(1): 284-292..

  37. Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo.: Dwivedi P, Kansal S, Sharma M, Shukla R, Verma AK, Shukla P, Tripathi P, Gupta PK, Saini D, Dwivedi AK,Mishra PR, (2012) Journal of Drug Targeting (JDT), 20(10): 883-96. DOI: 10.3109/1061186X.2012.725169

  38. Investigations on Alternate Approach to Target Mannose Receptors on Macrophages using 4-Sulfated N-Acetyl Galactosamine more Efficiently as Compared to Mannose Decorated Liposomes : An Applic: Singodia D, Verma A,Mishra PR, (2012) Nanomedicine-Nanotechnology, Biology and Medicine, 8(4): 468-477.. DOI: 10.1016/j.nano.2011.07.002

  39. Inhalable Microparticles Containing Nitric Oxide Donors: Saying NO to Intracellular Mycobacterium Tuberculosis: Singh AK, Mohan M, Agrawal AK, Verma PRP, Gupta A ,Misra A,Verma RK, (2012) Molecular Pharmaceutics, 9(11): 3183-3187 (IF:4.48). DOI: 10.1021/mp300269g

  40. Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to Rhesus macaques: Mukker JK, Singh RSP, Kumar K, Verma PRP, Misra A,Verma RK, (2012) Molecular Pharmaceutics, 9(4): 1011-1016 (IF:4.48). DOI: 10.1021/mp300043f

  41. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug delivery systems: Singh AK, Mohan M, Agrawal AK,Misra A, (2011) Therapeutic Delivery (Ther Delv.), 2(6): 753-768.. DOI: 10.4155/tde.11.34

  42. Nanoparticles Containing Nitric Oxide Donor with Antileishmanial Agent for Synergistic Effect Against Visceral Leishmaniasis: Pandya S,Misra A, (2011) Journal Biomedical Nanotechnology (JBN), 213-215. DOI: 10.1166/jbn.2011.1274

  43. RGD modified albumin nanospheres for tumour vasculature targeting: Dubey PK, Singodia D,Vyas SP, (2011) Journal Pharmacy and Pharmacology (JPP), 63(1): 33-40. DOI: 10.1111/j.2042-7158.2010.01180.x

  44. Loading and Release of Amphotericin-B from Biodegradable Poly (lactic-co-glycolic acid) Nanoparticles: Pandya S,Misra A, (2011) Journal Biomedical Nanotechnology (JBN), 7: 118-120. DOI: 10.1166/jbn.2011.1230

  45. Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis: Yadav AB, Muttil P, Singh AK,Mohan M, Sinha SK,Misra A, (2010) Tuberculosis, 90: 188-196 (IF:3.00). DOI: 10.1016/j.tube.2010.03.001

  46. The devil's advocacy: When and why inhaled therapies for tuberculosis may not work: Yadav AB, Muttil P, Singh, Mohan M,Misra A, (2010) Tuberculosis ( Elsevier), 9: 65-66. DOI: 10.1016/j.tube.2010.10.001

  47. Inhalable Microparticles Containing Isoniazid and Rifabutin Target Macrophages and Stimulate the Phagocyte” to Achieve High Efficacy: Yadav AB, Sharma R, Muttil P, Singh AK, Mohan M, Patel SK, (2009) Indian journal of Experimental Biology (IJEB), 1.46: 469-474. DOI: https://pubmed.ncbi.nlm.nih.gov/19634713/

  48. Intracellular time course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary delivery of inhalable Microparticles to Mice: Misra A,Kaur J, Kumar K, Yadav AB, (2008) Antimicrobial Agents and Chemotherapy (AAC), 52(9): 3195-3201. DOI: 10.1128/AAC.00153-08

  49. Apparatus for Pulmonary Delivery of Microparticles as a Dry Powder Inhalation Targeting Lung and Airway Macrophages in Mice: Kaur J, Muttil P, Kumar K, Yadav AB, Sharma R, Misra A, (2008) European Journal of Pharmaceutical sciences, 34: 56-65. DOI: 10.1016/j.ejps.2008.02.008

bottom of page